ClinicalTrials.gg
Active, not recruitingNCT04232553VIVID-2Updated Aug 11, 2026Results posted

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

A Phase 3 interventional study of Mirikizumab in Crohn's Disease, sponsored by Eli Lilly and Company. Active, not recruiting at 322 sites in 32 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
996
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing mirikizumab in Crohn Disease — 7 open to participants now, 8 under way, 3 of them phase 3. mirikizumab · Crohn Disease.

Enrollment
2nd of 10
996 · median 150
Started
2020
the only one that year
Phase 3
4 of 10
2 open now
Registered
3rd of 10
by date
Lead sponsor
5 of 10
Eli Lilly and Company

Among the 10 studies testing mirikizumab in Crohn Disease, this one is the 2nd largest by enrollment, is the only one that started in 2020, is one of 4 in phase 3, and was the 3rd registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

7 of the 10 studies testing mirikizumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About mirikizumab

mirikizumab: first FDA approval 2023 (OMVOH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing mirikizumab in Crohn Disease, or all of them as a file.
02

Study summary

The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.

03

Conditions studied

  • Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have completed study I6T-MC-AMAG (NCT02891226) or study I6T-MC-AMAM (NCT03926130)
  • If female, participant must meet the requirements

Exclusion criteria

Exclusion Criteria:

  • Participants must not have developed a new condition, including cancer in the previous study (I6T-MC-AMAG or I6T-MC-AMAM) that would pose an unacceptable risk in the trial.
  • Participants must not have any important infections including, but not limited to, , , /AIDS, and active tuberculosis (TB) during either previous study.

Note: Participants with a history of active TB with documentation of treatment by the Centers for Disease Control (CDC) and/or World Health Organization (WHO) criteria prior to the originator study are not excluded from the study.

  • Participants must not have a known to any component of mirikizumab or have experienced acute systemic hypersensitivity event with previous study drug administration in the originating study that precludes mirikizumab therapy.
  • Participation must not be pregnant, lactating, or planning to become pregnant while enrolled in the study or 16 weeks after receiving the last dose of study drug.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
996 participants (actual)

Study arms

  • Experimental
    AMAM Mirikizumab (Miri): Miri 300 mg SC

    Participants assigned to mirikizumab in Study AMAM who achieved Endoscopic Response at Week 52 of AMAM continued into Study AMAX and received mirikizumab 300 milligrams (mg) subcutaneously (SC) every 4 weeks (Q4W) for 52 weeks.

    Drug: Mirikizumab

  • Experimental
    AMAM Miri: Miri 900 mg IV Then 300 mg SC

    Participants assigned to mirikizumab in Study AMAM who did not achieve Endoscopic Response at Week 52 of AMAM continued into Study AMAX and received mirikizumab 900 mg intravenously (IV) Q4W for 3 doses, followed by mirikizumab 300 mg SC Q4W for 52 weeks.

    Drug: Mirikizumab

  • Experimental
    AMAM Placebo (PBO)/Miri: Miri 300 mg SC

    Participants assigned to placebo in Study AMAM who switched from placebo to mirikizumab at week 12 and achieved Endoscopic Response at Week 52 of AMAM continued into Study AMAX and received mirikizumab 300 mg SC Q4W for 52 weeks.

    Drug: Mirikizumab

  • Experimental
    AMAM PBO/Miri: Miri 900 mg IV Then 300 mg SC

    Participants assigned to placebo in Study AMAM who switched from placebo to mirikizumab at week 12 and did not achieve Endoscopic Response at Week 52 of AMAM continued into Study AMAX and received mirikizumab 900 mg IV Q4W for 3 doses, followed by mirikizumab 300 mg SC Q4W for 52 weeks.

    Drug: Mirikizumab

  • Experimental
    AMAM Ustekinumab (Uste): Miri 300 mg SC

    Participants assigned to ustekinumab in Study AMAM who achieved Endoscopic Response at Week 52 of AMAM continued into Study AMAX and received mirikizumab 300 mg SC Q4W for 52 weeks.

    Drug: Mirikizumab

  • Experimental
    AMAM Uste: Miri 900 mg IV Then 300 mg SC

    Participants assigned to ustekinumab in Study AMAM who did not achieve Endoscopic Response at Week 52 of AMAM continued into Study AMAX and received mirikizumab 900 mg IV Q4W for 3 doses, followed by mirikizumab 300 mg SC Q4W for 52 weeks.

    Drug: Mirikizumab

  • Experimental
    AMAM PBO: Miri 300 mg SC

    Participants assigned to placebo in Study AMAM who achieved Endoscopic Response at Week 52 of AMAM continued into Study AMAX and received mirikizumab 300 mg SC Q4W for 52 weeks.

    Drug: Mirikizumab

  • Experimental
    AMAM PBO: Miri 900 mg IV Then 300 mg SC

    Participants assigned to placebo in Study AMAM who did not achieve Endoscopic Response at Week 52 of AMAM continued into Study AMAX and received mirikizumab 900 mg IV Q4W for 3 doses, followed by mirikizumab 300 mg SC Q4W for 52 weeks.

    Drug: Mirikizumab

  • Experimental
    All AMAG Participants: Miri 300 mg SC

    Participants from Study AMAG who continued into Study AMAX received mirikizumab 300 mg SC Q4W for 52 weeks.

    Drug: Mirikizumab

Interventions

  • Administered Q4W

    Also known as: LY3074828

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Endoscopic Response at Week 52 (Participants Originating From AMAM Study)

    Endoscopic Response defined as ≥50% reduction from AMAM study baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) total score. The SES-CD evaluates 4 endoscopic variables (presence/size of ulcers, extent of ulcerated surface, extent of affected surface, and presence/severity of stenosis) across 5 ileocolonic bowel segments (ileum, right colon, transverse colon, left colon, and rectum), with each of the 4 variables scored from 0 (best) to 3 (worst) per segment, resulting in 20 individual assessments. Total SES-CD score is the sum of all 20 individual assessment scores across all the bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease.

    Time frame: Week 52

  2. Percentage of Participants Achieving Clinical Remission at Week 52 (Participants Originating From AMAM Study)

    Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) total score \< (less than) 150. The CDAI measures the severity of active disease using 8 disease variables: stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extra-intestinal manifestations, presence or absence of fistula, use or non-use of antidiarrheal agents, presence or absence of an abdominal mass, hematocrit, and body weight. Each variable is assigned a specific weight/multiplier, and the weighted values are summed to produce a CDAI total score. CDAI total scores can range from 0 to 600, with higher scores indicating more severe disease.

    Time frame: Week 52

Secondary outcomes

  1. Percentage of Participants Achieving Alternate Endoscopic Remission at Week 52 (Participants Originating From AMAM Study)

    Alternate endoscopic remission is defined as SES-CD Total Score ≤4 with at least a 2-point reduction from the AMAM study baseline and no subscore \>1. The SES-CD evaluates 4 endoscopic variables (presence/size of ulcers, extent of ulcerated surface, extent of affected surface, and presence/severity of stenosis) across 5 ileocolonic bowel segments (ileum, right colon, transverse colon, left colon, and rectum), with each of the 4 variables scored from 0 (best) to 3 (worst) per segment, resulting in 20 individual assessments. Total SES-CD score is the sum of all 20 individual assessment scores across all the bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease. No subscore \>1 is defined as no individual assessment score \>1 across all 20 individual assessments.

    Time frame: Week 52

  2. Percentage of Participants Achieving Clinical Response by Patient Reported Outcome (PRO) at Week 52 - (Participants Originating From AMAM Study)

    Clinical response by Patient Reported Outcome (PRO) was defined as a ≥30% decrease from baseline in stool frequency (SF) and/or abdominal pain (AP) score, with neither symptom worsening from baseline. SF was measured as the number of liquid or very soft stools per day. AP was scored daily on a 4-point scale: 0 = none, 1 = mild, 2 = moderate, and 3 = severe.

    Time frame: Week 52

  3. Fecal Calprotectin at Week 12 (Participants Originating From AMAM Study)

    Fecal calprotectin is an indicator of inflammation in the intestines with higher levels indicative of higher levels of inflammation.

    Time frame: Week 12

  4. C-Reactive Protein (CRP) at Week 12 (Participants Originating From AMAM Study)

    C-Reactive Protein is a biomarker of systemic inflammation measured in the blood, with elevated levels indicating increased inflammatory activity in the body.

    Time frame: Week 12

  5. Change From Baseline in Health Related Quality of Life at Week 52 : Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score (Participants Originating From AMAM Study)

    The Inflammatory Bowel Disease Questionnaire (IBDQ) is a 32-item participant completed questionnaire that measures 4 aspects of patients' lives: symptoms directly related to the primary bowel disturbance (10 items), systemic symptoms (5 items), emotional function (12 items), and social function(5 items). Responses are graded on a 7-point Likert scale in which 7 denotes "not a problem at all" and 1 denotes "a very severe problem." IBDQ total score is calculated as the sum of all questions. Total scores range from 32 to 224; a higher score indicates a better quality of life.

    Time frame: Baseline, Week 52

07

Results

Posted Dec 15, 2025

Participant flow

Eligibility for Study I6T-MC-AMAX (AMAX; NCT04232553) required completion of one of the originating studies: either Study I6T-MC-AMAM (AMAM; NCT03926130) or Study I6T-MC-AMAG (AMAG; NCT02891226). Participants from Study AMAM were classified as having achieved Endoscopic Response if they achieved a reduction from baseline in the Simple Endoscopic Score for Crohn's Disease \[SES-CD\] total score of greater than or equal to (\>=) 50% at Week 52.

Participant flow — Overall Study
MilestoneAMAM Mirikizumab (Miri): Miri 300 mg SCAMAM Miri: Miri 900 mg IV Then 300 mg SCAMAM Placebo (PBO)/Miri: Miri 300 mg SCAMAM PBO/Miri: Miri 900 mg IV Then 300 mg SCAMAM Ustekinumab (Uste): Miri 300 mg SCAMAM Uste: Miri 900 mg IV Then 300 mg SCAMAM PBO: Miri 300 mg SCAMAM PBO: Miri 900 mg IV Then 300 mg SCAll AMAG Participants: Miri 300 mg SC
Started28722229341381091853106
Received at least one dose of study drug28722229341381091853106
Completed27520928311331061851104
Not completed12131353022
Withdrew: Adverse event321211000
Withdrew: Death010100000
Withdrew: Lack of efficacy020000001
Withdrew: Lost to follow-up010010001
Withdrew: Other - as reported by the investigator010000000
Withdrew: Physician decision110010000
Withdrew: Pregnancy100000000
Withdrew: Withdrawal by subject750022020

Outcome measures

PrimaryPercentage of Participants Achieving Endoscopic Response at Week 52 (Participants Originating From AMAM Study)

Endoscopic Response defined as ≥50% reduction from AMAM study baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) total score. The SES-CD evaluates 4 endoscopic variables (presence/size of ulcers, extent of ulcerated surface, extent of affected surface, and presence/severity of stenosis) across 5 ileocolonic bowel segments (ileum, right colon, transverse colon, left colon, and rectum), with each of the 4 variables scored from 0 (best) to 3 (worst) per segment, resulting in 20 individual assessments. Total SES-CD score is the sum of all 20 individual assessment scores across all the bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Endoscopic Response at Week 52 (Participants Originating From AMAM Study)
percentage of participantsAMAM Miri: Miri 300 mg SCAMAM Miri: Miri 900 mg IV Then 300 mg SCAMAM PBO/Miri: Miri 300 mg SCAMAM PBO/Miri: Miri 900 mg IV Then 300 mg SCAMAM Uste: Miri 300 mg SCAMAM Uste: Miri 900 mg IV Then 300 mg SCAMAM PBO: Miri 300 mg SCAMAM PBO: Miri 900 mg IV Then 300 mg SC
Percentage of Participants Achieving Endoscopic Response at Week 52 (Participants Originating From AMAM Study)82.1 (77.4 to 86.8)29.7 (23.0 to 36.4)92.6 (82.7 to 100)38.7 (23.7 to 56.2)75.0 (67.3 to 82.7)39.7 (29.6 to 49.8)94.1 (82.6 to 100)51.4 (36.9 to 65.8)
PrimaryPercentage of Participants Achieving Clinical Remission at Week 52 (Participants Originating From AMAM Study)

Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) total score \< (less than) 150. The CDAI measures the severity of active disease using 8 disease variables: stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extra-intestinal manifestations, presence or absence of fistula, use or non-use of antidiarrheal agents, presence or absence of an abdominal mass, hematocrit, and body weight. Each variable is assigned a specific weight/multiplier, and the weighted values are summed to produce a CDAI total score. CDAI total scores can range from 0 to 600, with higher scores indicating more severe disease.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Remission at Week 52 (Participants Originating From AMAM Study)
percentage of participantsAMAM Miri: Miri 300 mg SCAMAM Miri: Miri 900 mg IV Then 300 mg SCAMAM PBO/Miri: Miri 300 mg SCAMAM PBO/Miri: Miri 900 mg IV Then 300 mg SCAMAM Uste: Miri 300 mg SCAMAM Uste: Miri 900 mg IV Then 300 mg SCAMAM PBO: Miri 300 mg SCAMAM PBO: Miri 900 mg IV Then 300 mg SC
Percentage of Participants Achieving Clinical Remission at Week 52 (Participants Originating From AMAM Study)79.2 (74.1 to 84.4)65.9 (58.8 to 72.9)76.6 (60.1 to 93.2)55.9 (37.6 to 74.2)75.8 (67.9 to 83.6)74.6 (65.2 to 84.0)84.9 (65.3 to 100)68.5 (53.8 to 83.1)
SecondaryPercentage of Participants Achieving Alternate Endoscopic Remission at Week 52 (Participants Originating From AMAM Study)

Alternate endoscopic remission is defined as SES-CD Total Score ≤4 with at least a 2-point reduction from the AMAM study baseline and no subscore \>1. The SES-CD evaluates 4 endoscopic variables (presence/size of ulcers, extent of ulcerated surface, extent of affected surface, and presence/severity of stenosis) across 5 ileocolonic bowel segments (ileum, right colon, transverse colon, left colon, and rectum), with each of the 4 variables scored from 0 (best) to 3 (worst) per segment, resulting in 20 individual assessments. Total SES-CD score is the sum of all 20 individual assessment scores across all the bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease. No subscore \>1 is defined as no individual assessment score \>1 across all 20 individual assessments.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Alternate Endoscopic Remission at Week 52 (Participants Originating From AMAM Study)
percentage of participantsAMAM Miri: Miri 300 mg SCAMAM Miri: Miri 900 mg IV Then 300 mg SCAMAM PBO/Miri: Miri 300 mg SCAMAM PBO/Miri: Miri 900 mg IV Then 300 mg SCAMAM Uste: Miri 300 mg SCAMAM Uste: Miri 900 mg IV Then 300 mg SCAMAM PBO: Miri 300 mg SCAMAM PBO: Miri 900 mg IV Then 300 mg SC
Percentage of Participants Achieving Alternate Endoscopic Remission at Week 52 (Participants Originating From AMAM Study)54.6 (48.4 to 60.7)14.2 (9.1 to 19.3)66.3 (48.0 to 84.5)25.8 (13.7 to 43.2)47.1 (38.3 to 56.0)22.1 (13.5 to 30.6)63.1 (39.6 to 86.6)32.6 (19.0 to 46.1)
SecondaryPercentage of Participants Achieving Clinical Response by Patient Reported Outcome (PRO) at Week 52 - (Participants Originating From AMAM Study)

Clinical response by Patient Reported Outcome (PRO) was defined as a ≥30% decrease from baseline in stool frequency (SF) and/or abdominal pain (AP) score, with neither symptom worsening from baseline. SF was measured as the number of liquid or very soft stools per day. AP was scored daily on a 4-point scale: 0 = none, 1 = mild, 2 = moderate, and 3 = severe.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Clinical Response by Patient Reported Outcome (PRO) at Week 52 - (Participants Originating From AMAM Study)
percentage of participantsAMAM Miri: Miri 300 mg SCAMAM Miri: Miri 900 mg IV Then 300 mg SCAMAM PBO/Miri: Miri 300 mg SCAMAM PBO/Miri: Miri 900 mg IV Then 300 mg SCAMAM Uste: Miri 300 mg SCAMAM Uste: Miri 900 mg IV Then 300 mg SCAMAM PBO: Miri 300 mg SCAMAM PBO: Miri 900 mg IV Then 300 mg SC
Percentage of Participants Achieving Clinical Response by Patient Reported Outcome (PRO) at Week 52 - (Participants Originating From AMAM Study)87.3 (83.1 to 91.4)74.7 (68.4 to 81.0)88.9 (76.8 to 100)63.3 (45.7 to 81.0)86.2 (80.1 to 92.3)84.0 (76.6 to 91.5)97.8 (86.4 to 100)78.2 (66.0 to 90.3)
SecondaryFecal Calprotectin at Week 12 (Participants Originating From AMAM Study)

Fecal calprotectin is an indicator of inflammation in the intestines with higher levels indicative of higher levels of inflammation.

Time frame:
Week 12
Reported as:
Median · micrograms per gram (μg/g)
Fecal Calprotectin at Week 12 (Participants Originating From AMAM Study)
micrograms per gram (μg/g)AMAM Miri: Miri 300 mg SCAMAM Miri: Miri 900 mg IV Then 300 mg SCAMAM PBO/Miri: Miri 300 mg SCAMAM PBO/Miri: Miri 900 mg IV Then 300 mg SCAMAM Uste: Miri 300 mg SCAMAM Uste: Miri 900 mg IV Then 300 mg SCAMAM PBO: Miri 300 mg SCAMAM PBO: Miri 900 mg IV Then 300 mg SC
Fecal Calprotectin at Week 12 (Participants Originating From AMAM Study)110.5 (37.0 to 293.0)310.0 (104.0 to 962.0)134.0 (15.0 to 484.0)168.0 (62.0 to 761.0)113.0 (40.0 to 364.0)312.5 (85.0 to 834.0)46.0 (15.0 to 415.0)333.5 (67.0 to 984.0)
SecondaryC-Reactive Protein (CRP) at Week 12 (Participants Originating From AMAM Study)

C-Reactive Protein is a biomarker of systemic inflammation measured in the blood, with elevated levels indicating increased inflammatory activity in the body.

Time frame:
Week 12
Reported as:
Median · milligram per liter (mg/L)
C-Reactive Protein (CRP) at Week 12 (Participants Originating From AMAM Study)
milligram per liter (mg/L)AMAM Miri: Miri 300 mg SCAMAM Miri: Miri 900 mg IV Then 300 mg SCAMAM PBO/Miri: Miri 300 mg SCAMAM PBO/Miri: Miri 900 mg IV Then 300 mg SCAMAM Uste: Miri 300 mg SCAMAM Uste: Miri 900 mg IV Then 300 mg SCAMAM PBO: Miri 300 mg SCAMAM PBO: Miri 900 mg IV Then 300 mg SC
C-Reactive Protein (CRP) at Week 12 (Participants Originating From AMAM Study)1.4 (0.6 to 4.6)2.7 (1.1 to 5.4)1.4 (1.0 to 5.0)3.2 (1.1 to 6.2)1.3 (0.6 to 3.8)3.5 (0.9 to 6.8)2.3 (0.4 to 4.7)3.7 (1.3 to 7.3)
SecondaryChange From Baseline in Health Related Quality of Life at Week 52 : Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score (Participants Originating From AMAM Study)

The Inflammatory Bowel Disease Questionnaire (IBDQ) is a 32-item participant completed questionnaire that measures 4 aspects of patients' lives: symptoms directly related to the primary bowel disturbance (10 items), systemic symptoms (5 items), emotional function (12 items), and social function(5 items). Responses are graded on a 7-point Likert scale in which 7 denotes "not a problem at all" and 1 denotes "a very severe problem." IBDQ total score is calculated as the sum of all questions. Total scores range from 32 to 224; a higher score indicates a better quality of life.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Health Related Quality of Life at Week 52 : Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score (Participants Originating From AMAM Study)
score on a scaleAMAM Miri: Miri 300 mg SCAMAM Miri: Miri 900 mg IV Then 300 mg SCAMAM PBO/Miri: Miri 300 mg SCAMAM PBO/Miri: Miri 900 mg IV Then 300 mg SCAMAM Uste: Miri 300 mg SCAMAM Uste: Miri 900 mg IV Then 300 mg SCAMAM PBO: Miri 300 mg SCAMAM PBO: Miri 900 mg IV Then 300 mg SC
Change From Baseline in Health Related Quality of Life at Week 52 : Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score (Participants Originating From AMAM Study)57.3 ± 1.9946.1 ± 2.3247.4 ± 6.1238.6 ± 5.8150.5 ± 2.8249.9 ± 3.2965.3 ± 7.8446.4 ± 4.62

Adverse events

Collected over Baseline Up to Week 52. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AMAM Miri: Miri 300 mg SC0/287 (0%)19/287 (6.6%)189/287 (65.9%)
AMAM Miri: Miri 900 mg IV Then 300 mg SC1/222 (0.5%)20/222 (9%)138/222 (62.2%)
AMAM PBO/Miri: Miri 300 mg SC0/29 (0%)1/29 (3.4%)16/29 (55.2%)
AMAM PBO/Miri: Miri 900 mg IV Then 300 mg SC1/34 (2.9%)8/34 (23.5%)21/34 (61.8%)
AMAM Uste: Miri 300 mg SC0/138 (0%)9/138 (6.5%)82/138 (59.4%)
AMAM Uste: Miri 900 mg IV Then 300 mg SC0/109 (0%)9/109 (8.3%)69/109 (63.3%)
AMAM PBO: Miri 300 mg SC0/18 (0%)0/18 (0%)12/18 (66.7%)
AMAM PBO: Miri 900 mg IV Then 300 mg SC0/53 (0%)7/53 (13.2%)33/53 (62.3%)
All AMAG Participants: Miri 300 mg SC0/106 (0%)3/106 (2.8%)68/106 (64.2%)
Most frequent serious events
Showing 10 of 51
Most frequent serious events
EventAMAM Miri: Miri 300 mg SCAMAM Miri: Miri 900 mg IV Then 300 mg SCAMAM PBO/Miri: Miri 300 mg SCAMAM PBO/Miri: Miri 900 mg IV Then 300 mg SCAMAM Uste: Miri 300 mg SCAMAM Uste: Miri 900 mg IV Then 300 mg SCAMAM PBO: Miri 300 mg SCAMAM PBO: Miri 900 mg IV Then 300 mg SCAll AMAG Participants: Miri 300 mg SC
Crohn's diseaseGastrointestinal disorders2/2871/2220/293/343/1382/1090/181/531/106
Ileal stenosisGastrointestinal disorders0/2870/2220/290/340/1380/1090/182/530/106
Cerebrovascular accidentNervous system disorders0/2870/2221/290/340/1380/1090/180/530/106
Small intestinal obstructionGastrointestinal disorders0/2871/2220/291/341/1380/1090/180/530/106
Post procedural infectionInfections and infestations0/2870/2220/291/340/1380/1090/180/530/106
Transaminases increasedInvestigations0/2870/2220/291/340/1380/1090/180/530/106
ArthropathyMusculoskeletal and connective tissue disorders0/2870/2220/291/340/1380/1090/180/530/106
Rotator cuff syndromeMusculoskeletal and connective tissue disorders0/2870/2220/291/340/1380/1090/180/530/106
Anal fistulaGastrointestinal disorders0/2870/2220/290/341/1380/1090/181/530/106
IleusGastrointestinal disorders0/2871/2220/290/340/1380/1090/181/530/106
Most frequent other events
Showing 10 of 583
Most frequent other events
EventAMAM Miri: Miri 300 mg SCAMAM Miri: Miri 900 mg IV Then 300 mg SCAMAM PBO/Miri: Miri 300 mg SCAMAM PBO/Miri: Miri 900 mg IV Then 300 mg SCAMAM Uste: Miri 300 mg SCAMAM Uste: Miri 900 mg IV Then 300 mg SCAMAM PBO: Miri 300 mg SCAMAM PBO: Miri 900 mg IV Then 300 mg SCAll AMAG Participants: Miri 300 mg SC
Covid-19Infections and infestations35/28725/2222/292/3412/13814/1095/187/5312/106
DiarrhoeaGastrointestinal disorders9/2879/2220/290/342/1384/1092/180/532/106
NasopharyngitisInfections and infestations19/2870/2222/290/347/1385/1092/185/536/106
HeadacheNervous system disorders10/2878/2220/290/343/1384/1090/182/5311/106
AlopeciaSkin and subcutaneous tissue disorders1/2871/2223/290/341/1381/1090/180/531/106
Vulvovaginal candidiasisInfections and infestations0/1241/880/171/110/700/540/70/210/49
EndometriosisReproductive system and breast disorders0/1240/880/171/110/700/540/70/210/49
AnaemiaBlood and lymphatic system disorders10/2874/2221/293/347/1384/1091/182/531/106
Penile painReproductive system and breast disorders0/1630/1341/120/230/680/550/110/320/57
ProstatitisReproductive system and breast disorders1/1630/1341/120/230/680/550/110/320/57

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)AMAM Miri: Miri 300 mg SCAMAM Miri: Miri 900 mg IV Then 300 mg SCAMAM PBO/Miri: Miri 300 mg SCAMAM PBO/Miri: Miri 900 mg IV Then 300 mg SCAMAM Uste: Miri 300 mg SCAMAM Uste: Miri 900 mg IV Then 300 mg SCAMAM PBO: Miri 300 mg SCAMAM PBO: Miri 900 mg IV Then 300 mg SCAll AMAG Participants: Miri 300 mg SCTotal
Mean37.2 ± 12.8438.4 ± 13.6639.5 ± 16.0037.7 ± 11.9239.2 ± 12.8437.6 ± 12.6837.6 ± 9.5238.0 ± 12.8841.5 ± 12.2038.4 ± 12.98
Sex: Female, Male
Sex: Female, Male(Participants)AMAM Miri: Miri 300 mg SCAMAM Miri: Miri 900 mg IV Then 300 mg SCAMAM PBO/Miri: Miri 300 mg SCAMAM PBO/Miri: Miri 900 mg IV Then 300 mg SCAMAM Uste: Miri 300 mg SCAMAM Uste: Miri 900 mg IV Then 300 mg SCAMAM PBO: Miri 300 mg SCAMAM PBO: Miri 900 mg IV Then 300 mg SCAll AMAG Participants: Miri 300 mg SCTotal
Female124881711705472149441
Male16313412236855113257555
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AMAM Miri: Miri 300 mg SCAMAM Miri: Miri 900 mg IV Then 300 mg SCAMAM PBO/Miri: Miri 300 mg SCAMAM PBO/Miri: Miri 900 mg IV Then 300 mg SCAMAM Uste: Miri 300 mg SCAMAM Uste: Miri 900 mg IV Then 300 mg SCAMAM PBO: Miri 300 mg SCAMAM PBO: Miri 900 mg IV Then 300 mg SCAll AMAG Participants: Miri 300 mg SCTotal
American Indian or Alaska Native1100110206
Asian68617531213613215
Native Hawaiian or Other Pacific Islander0000000000
Black or African American45013300723
White207154212610284144585738
More than one race2000100014
Unknown or Not Reported51120010010
Region of Enrollment
Region of Enrollment(Participants)AMAM Miri: Miri 300 mg SCAMAM Miri: Miri 900 mg IV Then 300 mg SCAMAM PBO/Miri: Miri 300 mg SCAMAM PBO/Miri: Miri 900 mg IV Then 300 mg SCAMAM Uste: Miri 300 mg SCAMAM Uste: Miri 900 mg IV Then 300 mg SCAMAM PBO: Miri 300 mg SCAMAM PBO: Miri 900 mg IV Then 300 mg SCAll AMAG Participants: Miri 300 mg SCTotal
Argentina1000000001
Australia34010004113
Austria1500120009
Belgium23010101311
Brazil1411037723047
Canada114405311029
China3432541016040105
Croatia5000000005
Czechia1214528722658
France1101000003
Germany154102522031
Hungary103115511431
India46105100017
Israel3100010308
Italy1101000003
Japan650192011337
Latvia0000200002
Lithuania1100100104
Mexico3100110107
Netherlands0110100058
Poland40330417222816142
Romania55001110417
Russia18182511518674
Serbia41423202018
Slovakia34003301014
South Korea2117106231051
Switzerland2101200006
Turkey159111502034
Ukraine2211231811211383
United Kingdom4000000004
United States2626131971635124
08

Study locations

322 sites

Showing the first 100 of 322 sites across 32 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Sands BE, Barnes EL, D'Haens G, Hisamatsu T, Regueiro M, Kelly CR, Laharie D, Hozak RR, Yu G, Gandhi R A, Lopes MU, Durand F, Protic M, Moses RE, Vermeire S. Mirikizumab Long-Term Efficacy and Safety in Patients With Crohn's Disease: Results From the VIVID-2 Open-Label Extension Trial. Clin Gastroenterol Hepatol. 2026 Mar 5:S1542-3565(26)00155-2. doi: 10.1016/j.cgh.2026.01.049. Online ahead of print. PubMed 41794217 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Nov 2024, 53 months.

Results were first posted in Dec 2025, 1 year after primary completion.

Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's 53 months is above that.

Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2020
First posted
Jan 18, 2020
StartActual
Jun 22, 2020
Primary completionActual
Nov 28, 2024
CompletionEst.
Mar 2028
Results first posted
Dec 15, 2025
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04232553
Responsible party
Sponsor
First posted
Jan 18, 2020
Start date
Jun 22, 2020
Primary completion
Nov 28, 2024
Completion
Mar 2028 (estimated)
Results posted
Dec 15, 2025
Last update
Aug 11, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM -5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirikizumab

Start the discussion